Curium
Curium is one of the largest nuclear-medicine companies, developing 177Lu-PSMA-I&T (ECLIPSE) as a competitor to Pluvicto.
Overview
Curium is a Paris-based private radiopharmaceutical group, one of the largest in nuclear medicine, supplying SPECT and PET isotopes and generators and developing 177Lu-PSMA-I&T as a competitor to Pluvicto in prostate cancer. Its ECLIPSE phase 3 trial of 177Lu-PSMA-I&T met its radiographic progression-free survival endpoint in taxane-naive metastatic castration-resistant prostate cancer, a Japanese registrational trial with PeptiDream and PDRadiopharma enrolled its first patient in February 2026, and the regulatory submission plan is under discussion with the FDA. Nuclide links it to DOTATATE imaging agents, samarium-153 lexidronam, radionuclide generators and the therapeutic isotope supply chain. Whether a second lutetium PSMA agent can differentiate on supply and price rather than efficacy is the open question. The manufacturing cost of radioactive medicines is the bottleneck it bears on.
Scorecard
All companies- approved products +48
- phase 3 +3
- targets +4
- modalities +6
- regions +3
- 24-month regulatory events +2
- registry trials +22
Manufacturing
Capacity map- Curium Petten Petten, NLRadioisotope production, Radiopharmaceutical manufacturing
177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.
An injectable tracer that sticks to a marker (somatostatin receptor) many neuroendocrine tumours carry. A PET scan afterwards shows where those tumours are, including small deposits that other scans can miss.
One of the oldest cancer-imaging scans still on the market: an injectable form of radioactive gallium that collects in lymphomas and some other tumours (and in infections), imaged one to five days later. It has mostly been replaced by FDG-PET but is still FDA-approved and occasionally used.
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
The original nuclear medicine scan for finding neuroendocrine tumours, used before PET scans like Ga-68 DOTATATE became available. It is still FDA-approved but has largely been superseded because PET gives sharper pictures with less radiation.
A second, cheaper version of an already-approved radioactive drug for neuroendocrine tumours has been approved, using the same active radioactive ingredient as the original but made by a different company.
Quadramet (samarium-153 lexidronam) is a radioactive bone-seeking injection that lodges in bone metastases and irradiates them from inside, approved in 1997 to relieve pain from prostate, breast and other cancers spread to bone. Most patients get relief within one to two weeks, but marrow suppression follows at three to five weeks, and radium-223 and PSMA radioligands have largely replaced it.
Tiny clumps of albumin, a normal blood protein, tagged with a radioactive marker and injected into a vein. They wedge briefly in the smallest blood vessels of the lung wherever blood is flowing, so the scan maps the lung's blood supply; the clumps then break up and clear.
The standard, decades-old bone scan: a radioactive tracer that sticks to areas of bone rebuilding, so a gamma-camera picture afterwards shows where cancer may have spread to bone, or where a fracture or infection is healing.
Similar pages
not linked directly; found by shared links- CompanyIRE (Institut national des Radioéléments)
Shares Molybdenum-99 supply, Radionuclide generators and cold kits, Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
- CompanyNTP Radioisotopes
Shares Enriched target material for therapeutic isotopes, Molybdenum-99 supply, Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
- CompanyANSTO (Australian Nuclear Science and Technology Organisation)
Shares Molybdenum-99 supply, Molybdenum-99, Radiopharmacy and cyclotron networks, Research reactors for medical isotopes (Mo-99, Lu-177, I-131).
- CompanyLantheus
Shares Samarium-153, Samarium-153 lexidronam, 177Lu-PSMA-I&T, Radionuclide generators and cold kits.
- CompanyEckert & Ziegler
Shares Radionuclide generators and cold kits, Radiopharmacy and cyclotron networks, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- CompanySHINE Technologies
Shares Molybdenum-99 supply, Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).
- TermRadionuclidic purity
Shares Radionuclide generators and cold kits, Molybdenum-99, Radiopharmaceutical GMP and releasing a drug that decays, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).
- CompanyNorthStar Medical Radioisotopes
Shares Molybdenum-99 supply, Molybdenum-99, Research reactors for medical isotopes (Mo-99, Lu-177, I-131), Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225).